menu

ReachMD

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Change the Story: Preventing Missteps With Invasive Fungal Infections  

close
1.00 credits
60 minutes
Change the Story: Preventing Missteps With Invasive Fungal Infections
Restart
Resume
Read full article
Choose a format
Get your free creditsSkip straight to the post-test if you have already participated in this activity
Media formats available:
1.00 credits
A pre-test is required to view this content.
A pre-survey is required to view this content.
Details
Presenters
Comments
  • Overview

    Have you ever wondered what went wrong in the management of invasive fungal infections?  Through a storytelling approach Dr. James Lewis & Dr. George Thompson discuss a clinical story and identify where medical misses may have occurred.  Supportive evidence will be provided on how care should have been provided and strategies for clinicians to apply in their practice.

  • Commercial Support

    Supported by an educational grant from Astellas.

  • Learning Objectives

    Upon completion of this activity, participants will be able to:

    • Implement evidence-based diagnostic strategies for invasive fungal infections associated with Aspergillus and mucormycetes
    • Interpret data on the pharmacokinetic/pharmacodynamic properties, efficacy, and safety profiles of the triazoles
    • Formulate individualized treatment strategies for diverse patients with or at risk for fungal infections associated with aspergillosis and mucormycosis 
  • Target Audience

    This educational activity is designed for infectious disease clinicians, oncologists/hematologists, critical care specialists and the multidisciplinary healthcare team who are involved in the care of patients with or at risk for invasive fungal infections.

  • Accreditation and Credit Designation Statements

    The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.

  • Method of Participation

    This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

  • Disclosure of Conflicts of Interest

    The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

    The following financial relationships have been provided:

    James Lewis II, PharmD, FIDSA
    Consulting Agreements: Merck

    George Thompson III, MD, FIDSA 
    Consultant: Amplyx Pharmaceuticals, Inc., Astellas, F2G, Mayne Pharma, Pfizer
    Grant/Research Support: Amplyx Pharmaceuticals, Inc., Astellas, F2G, Mayne Pharma, Pfizer, Toyoma Pharmaceuticals

    Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Non-FDA approved use of available antifungal therapies

    ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. 

  • ACHL Disclaimer

    The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

    This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.  Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

    This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

    Names and details used in this educational activity have been changed to protect patient privacy.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Recommended
Details
Presenters
Comments
  • Overview

    Have you ever wondered what went wrong in the management of invasive fungal infections?  Through a storytelling approach Dr. James Lewis & Dr. George Thompson discuss a clinical story and identify where medical misses may have occurred.  Supportive evidence will be provided on how care should have been provided and strategies for clinicians to apply in their practice.

  • Commercial Support

    Supported by an educational grant from Astellas.

  • Learning Objectives

    Upon completion of this activity, participants will be able to:

    • Implement evidence-based diagnostic strategies for invasive fungal infections associated with Aspergillus and mucormycetes
    • Interpret data on the pharmacokinetic/pharmacodynamic properties, efficacy, and safety profiles of the triazoles
    • Formulate individualized treatment strategies for diverse patients with or at risk for fungal infections associated with aspergillosis and mucormycosis 
  • Target Audience

    This educational activity is designed for infectious disease clinicians, oncologists/hematologists, critical care specialists and the multidisciplinary healthcare team who are involved in the care of patients with or at risk for invasive fungal infections.

  • Accreditation and Credit Designation Statements

    The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Completion of this activity, including the pretest, posttest, and follow-up assessments, qualifies as a medium weight MIPS improvement activity under MACRA and can be claimed as completion of IA_PSPA 28 of an Accredited Safety or Quality Improvement Program in the Quality Payment Program. Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website. You will receive additional information after completing the activity and receiving your certificate via email.

  • Method of Participation

    This activity will take approximately 60 minutes to complete. To receive credit, participants are required to complete the pretest, view the online activity and complete the posttest and evaluation. To receive credit, 80% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.

  • Disclosure of Conflicts of Interest

    The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been mitigated prior to this activity.

    The following financial relationships have been provided:

    James Lewis II, PharmD, FIDSA
    Consulting Agreements: Merck

    George Thompson III, MD, FIDSA 
    Consultant: Amplyx Pharmaceuticals, Inc., Astellas, F2G, Mayne Pharma, Pfizer
    Grant/Research Support: Amplyx Pharmaceuticals, Inc., Astellas, F2G, Mayne Pharma, Pfizer, Toyoma Pharmaceuticals

    Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Non-FDA approved use of available antifungal therapies

    ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose. 

  • ACHL Disclaimer

    The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.

    This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education.  Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.

    This CME/CE activity might describe the off-label, investigational, or experimental use of medications that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.

    Names and details used in this educational activity have been changed to protect patient privacy.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

Programs 6/13/21